Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440136 | 0.78 | TSHR (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL12516496 | 0.78 | ALDH1A1 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL12440333 | 0.78 | ALDH1A1 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL25019697 | 0.77 | CA12 (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3CA12 | |
| SCHEMBL12987377 | 0.76 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CA12 | |
| SCHEMBL23125435 | 0.73 | TSHR (0.38) | CA12CA1CA2CA9TSHR | |
| SCHEMBL24477538 | 0.73 | PIK3CD (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL29011828 | 0.73 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL14011288 | 0.73 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3CA12 | |
| SCHEMBL11682685 | 0.73 | CA1 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954250-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954250-B2 | Prodrugs of secondary amine compounds | HNMT, MAOB, UGT1A1 | CHRNB2 1011/4885CHRNA4 1587/4885CHRNB4 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.